| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1dfad69817255df7917f7eccc71319fe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_59a43eee6edfbb2d1a8446a9d9c21e9e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a07d4fc6fb47617a42e4600c964cd7eb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8e9128754c5c7d46eb8811fd0d2130aa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e3310a7a3426cb2e8dd4539adfbca231
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bf7fb7e404501e015ae5847d650c53de |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55561
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-315
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-313 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-117
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-117
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7088 |
| filingDate |
2009-11-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a9a4daee91cce37bb83b44f93c918c39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3571ff5424ffa71a1257eeb553b0d230
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_013019a5bde3a0259c6d0040b24fe3bc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9ab8111cc0a2130fd0ff842454655c3c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ba28c797eaad4a27194a2d9da4791876 |
| publicationDate |
2010-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2010053435-A2 |
| titleOfInvention |
Compounds and methods for the treatment of inflammatory diseases of the cns |
| abstract |
Inflammatory diseases in the CNS can be treated or alleviated by the administration of an oligonucleotide in an amount sufficient to reduce the influx of mononuclear cells to the central nervous system by down-regulating the expression of at least one cell surface marker. For example multiple sclerosis can be treated or at least alleviated, by the administration of an oligonucleotide in a dose effective to inhibit or reduce the influx of mononuclear and/or autoaggressive cells to the central nervous system. The oligonucleotide can be used alone, or in combination with other treatment strategies. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2468866-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9795627-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2015504438-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9492516-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012084993-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012084991-A1 |
| priorityDate |
2008-11-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |